Program Description
Precision medicine has fundamentally altered the management of non-small cell
lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer
diagnoses and remains a leading cause of cancer-related mortality. Biomarker
testing is critical in NSCLC because it identifies specific genetic alterations
that allow for the selection of targeted therapies, which have been shown to
significantly improve progression-free survival and reduce systemic toxicity
compared with traditional chemotherapy. Given the significant treatment burden
and the complexity of the therapeutic landscape, identifying targetable genomic
alterations is now becoming standard in NSCLC treatment and management plans.
This session reviews the pharmacist’s role in navigating biomarker testing in
NSCLC, from initial sample acquisition to the application of targeted
therapies. Faculty experts will examine current guideline recommendations for
mutational and genomic testing and address practical testing pearls, such as
tissue requirements, turnaround times, and the logistics of coordination.
Strategies for interpreting complex genomic reports using evidence-based
resources will also be outlined. By reviewing institutional models and
pharmacist-led interventions, including participation in molecular tumor boards
and the utilization of EMR-based clinical decision support tools, oncology
pharmacists will gain insights into overcoming common implementation barriers
affecting practice.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: .75 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain current guideline recommendations for biomarker, mutational, and genomic testing in non-small cell lung cancer (NSCLC)
- Identify the advancing role of pharmacists in supporting personalized care through biomarker testing and targeted therapeutic strategies
- Document best practices that have optimized biomarker testing workflows in NSCLC
Syed Zia Khan, PharmD, BCSCP
Director of Pharmacy
The START Center for Cancer Care
San Antonio, TX
Mya Tran, PharmD, BCOP
Precision Oncology Clinical Pharmacist
Indiana University Health – Simon Comprehensive Cancer Center
Indianapolis, IN
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-26-111-H01-P. The activity is available for CE credit through May 12, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Syed Zia Khan, PharmD, BCSCP
Mya Tran, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP, Daphne Davis, PharmD, BCOP; Emily Tyler; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here